The United Kingdom and the United States have agreed to a important bilateral deal that will preserve no import taxes on UK drug exports being sold in the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to raise expenditure on medicines through the NHS. This commitment guarantees that duties on these vital products will be held at zero for a duration of three years.
This development follows earlier threats to hike tariffs on branded pharmaceutical products, with increases discussed reaching double the cost.
"This agreement between the UK reinforces the global environment for innovative medicines and establishes long-overdue fairness to American-British drug exports," an announcement said.
Economic Importance
Medicines constitute one of the Britain's biggest export categories to the America, which is by far the largest market for large British pharmaceutical firms.
Statistics reveal that in the 12 months to the end of the third quarter, the UK exported drugs totaling over eleven billion pounds to the US. This value made up a significant portion of total UK exports in that timeframe.
"This guarantee secures employment, boosts capital expenditure and paves the way for the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary stated.
Detailed UK Commitments
The pact includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase total public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must refund to the NHS to control costs will be limited at 15%. Last year, refunds topped 20%.
Broader Context
The pact takes place against a ongoing dispute between the sector and the British authorities over medicine costs and NHS adoption.
The disagreement were heightened by arguments that US patients were paying several times more for the equivalent treatments than patients in the UK and Europe.
Recently, several large drug company projects in the UK have been delayed or abandoned, while major expansions have been directed toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had declined as a proportion of its total funding over the last ten years.
